ALX ONCOLOGY HOLDINGS INC (ALXO) Current Ratio
- Current ratio · latest quarter: Value 9.71×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 9.71× | Current assets / current liabilities. $143.46M ÷ $14.78M ≈ 9.71× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 143.46M USD | Assets, Current |
| Current obligations | 14.78M USD | Liabilities, Current |
| Cash and equivalents | 22.69M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.02M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $143.46M | $14.78M | $22.69M | (m) | (m) | (m) | $3.02M | $0.00 | 9.71× |
| 2026-03-31 | $145.56M | $20.18M | $32.28M | (m) | (m) | (m) | $3.85M | $5.22M | 7.21× |
| 2025-12-31 | $50.73M | $24.55M | $16.37M | (m) | (m) | (m) | $4.91M | $5.22M | 2.07× |
| 2025-09-30 | $66.52M | $27.72M | $23.44M | (m) | (m) | (m) | $6.58M | $4.35M | 2.40× |
| 2025-06-30 | $85.26M | $18.85M | $19.30M | (m) | (m) | (m) | $4.90M | $3.04M | 4.52× |
| 2025-03-31 | $102.53M | $18.74M | $20.61M | (m) | (m) | (m) | $3.94M | $1.74M | 5.47× |
| 2024-12-31 | $134.35M | $18.50M | $17.57M | (m) | (m) | (m) | $4.50M | $435.00K | 7.26× |
| 2024-09-30 | $155.90M | $32.34M | $16.10M | (m) | (m) | (m) | $7.89M | $0.00 | 4.82× |
| 2024-06-30 | $168.71M | $38.45M | $15.53M | (m) | (m) | (m) | $8.15M | $0.00 | 4.39× |
| 2024-03-31 | $167.86M | $32.23M | $14.04M | (m) | (m) | (m) | $6.23M | $0.00 | 5.21× |
| 2023-12-31 | $188.66M | $36.00M | $22.41M | (m) | (m) | (m) | $8.59M | (m) | 5.24× |
| 2023-09-30 | $199.07M | $35.14M | $19.58M | (m) | (m) | (m) | $13.00M | $0.00 | 5.66× |
| 2023-06-30 | $219.56M | $17.57M | $38.04M | (m) | (m) | (m) | $4.12M | $0.00 | 12.49× |
| 2023-03-31 | $232.54M | $21.89M | $63.19M | (m) | (m) | (m) | $9.83M | $0.00 | 10.62× |
| 2022-12-31 | $270.97M | $28.32M | $48.82M | (m) | (m) | (m) | $8.07M | (m) | 9.57× |
| 2022-09-30 | $290.81M | $25.24M | $49.05M | (m) | (m) | (m) | $5.88M | (m) | 11.52× |
| 2022-06-30 | $316.85M | $23.95M | $66.38M | (m) | (m) | (m) | $8.68M | (m) | 13.23× |
| 2022-03-31 | $321.52M | $15.31M | $159.09M | (m) | (m) | (m) | $5.13M | (m) | 21.00× |
| 2021-12-31 | $367.02M | $15.29M | $363.67M | (m) | (m) | (m) | $3.76M | (m) | 24.00× |
| 2021-09-30 | $388.96M | $12.49M | $385.15M | (m) | (m) | (m) | $3.68M | (m) | 31.15× |
| 2021-06-30 | $412.28M | $13.98M | $409.96M | (m) | (m) | (m) | $5.81M | (m) | 29.49× |
| 2021-03-31 | $432.33M | $14.13M | $429.86M | (m) | (m) | (m) | $7.35M | (m) | 30.60× |
| 2020-12-31 | $435.99M | $6.20M | $434.22M | (m) | (m) | (m) | $4.00K | (m) | 70.28× |
| 2020-09-30 | $262.40M | $7.20M | $259.48M | (m) | (m) | (m) | $1.42M | $2.57M | 36.46× |
| 2020-06-30 | $100.66M | $7.72M | $98.10M | (m) | (m) | (m) | $1.86M | $1.71M | 13.04× |
| 2019-12-31 | $9.81M | $4.98M | $9.02M | (m) | (m) | (m) | $3.75M | (m) | 1.97× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |